[OC-05] Gene & Cell Therapy for Neurological Diseases

[OC-05-3] in vivo Gene Therapy for GM2 Gangliosidoses

^○Kohji Itoh^1,5, Daisuke Tsuji¹, Kyo-ya Ohnishi¹, Ryo-suke Watanabe², Katsuhito Asai^3,5, Shin-ichi Muramatsu^4,5 (1.Department of Medicinal Biotechnology, Graduate School of Biomedical Sciences. Tokushima University, Japan, 2.Faculty of Pharmaceutical Sciences, Tokushima University, Japan, 3.Gene Therapy Research Institute, Co., Ltd., Japan, 4.Division of Neurology, Jichi Medical University, Japan, 5.TR-SPRINT, AMED, Japan)

Education
1977-1981 Kyoto Univ. B.S. - Pharmacy
1981-1983 Sch. of Pharmaceut. Sci., Kyoto Univ., M.S. - Pharmaceut. Sci.
1983-1986 Grad. Sch. of Pharmaceut. Sci., The Tokyo University Ph.D.

Professional Carrier:
1986-1999 Research Scientist (1995~1999 Chief Scientist)
The Tokyo Metropol. lnstit. of Medi. Sci., Tokyo, Japan
1999- Professor (2009- Director), Dept. of Medicin. Biotechnol.,
Inst. for Medicin. Res., Grad. Scl. of P harmaceut. Sci.,Tokushima Univ., Japan

Grants and Awards:
2004-2008 JST CREST Group Research Director
2009-2013 NIBIO Subdirector
2010-2014 MAFF Promot. of Appl. Res. for Agrihealth Sci. PT Subdirector
2013-2015 MEXT KAKENHI (Scientific Research on Innovative Areas)
2014-2016 MEXT KAKENHI (Basic Research, B)
2016-2017 AMED ACT-MS
2017- AMED TR-SPRINT

Research fields: Lysosomal storage diseases, Molecular pathogenesis and therapy